Walgreens Boots Alliance stock is supported by earnings and debt metrics

Walgreens Boots Alliance (US9314271019) remains a numbers-driven story after the company reported fiscal 2025 revenue of $147.7 billion, adjusted EPS of $1.57, and adjusted operating income of $1.3 billion. Those figures set the baseline for Walgreens Boots Alliance stock as the market weighs profitability against scale and leverage.

Revenue and earnings reset the frame

The fiscal 2025 revenue figure of $147.7 billion gives the group size, but the more important detail is the modest adjusted EPS of $1.57 and the $1.3 billion adjusted operating income reported for the year. Together, they show a business still generating very large turnover while operating with thin margins.

That combination matters because Walgreens has to convert sales into cash more efficiently before the equity story can improve meaningfully. For now, the annual report numbers suggest investors are still focusing on earnings quality rather than headline revenue alone.

Debt remains part of the equation

Walgreens Boots Alliance also reported long-term debt of $8.7 billion and total current liabilities of $35.2 billion in fiscal 2025. Against fiscal 2025 revenue of $147.7 billion, those balance-sheet figures help explain why the market still treats execution and cash generation as central.

The comparison is straightforward: a company with $147.7 billion in annual sales and $1.3 billion in adjusted operating income has limited room for operational misses. That gap between scale and profitability is what continues to define the stock.

Margin pressure is the key number

Fiscal 2025 adjusted operating income of $1.3 billion against $147.7 billion of revenue leaves the company with a narrow operating cushion. That ratio is the cleanest way to understand why the equity remains sensitive to even small changes in margin, pharmacy mix, or cost control.

In practical terms, the market is not looking for spectacle from Walgreens Boots Alliance stock. It is looking for better conversion of sales into profit, and the fiscal 2025 data show how much work remains.

Retail pharmacy remains the core

Walgreens Boots Alliance built its business around retail pharmacy, health and beauty products, and related services through Walgreens and Boots stores. The company's scale helps support the model, but the fiscal 2025 figures show that the consumer-facing network still has to produce better earnings power to translate into equity upside.

That is the main product-level takeaway from the latest annual numbers: the store network is large, but profitability is the bottleneck. The stock story follows that bottleneck.

Stock level and market value

Walgreens Boots Alliance stock has been assessed here through its latest annual financial metrics rather than a live trading quote. The relevant market frame remains the fiscal 2025 backdrop of $147.7 billion in revenue, $1.57 adjusted EPS, and $1.3 billion adjusted operating income.

For investors, the decisive reference is still the earnings base, not a one-day headline move. When the company can show stronger profit conversion from its revenue scale, the valuation case becomes easier to read.